Alzheimer’s disease <i>APOE</i> neuropathology‐based score, amyloid, and ptau polygenic scores’ association with amyloid PET positivity

These results validate the utility of the APOEscore with PET amyloid as well as the potential value of including non-APOE genes in quantifying the genetic risk for amyloid accumulation and AD. The significant association between amyloid-PGS and A+, and near significance after adding the APOEscore, demonstrates the existence of additional genetic effects outside of APOE that have an impact on amyloid accumulation. While the ptau-PGS did not reach significance, possibly due to sample size, the OR (3.218) was greater in magnitude than the amyloid-PGS (1/OR = 2.033). Future work will explore these relationships in other cohorts and with other PET AD biomarkers.